
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.
In the month of June 2026, the dermatology field saw a significant number of major developments in terms of new treatment data,






